However, in a phase 2 study, limsitinib, the most extensively evaluated IGF1R inhibitor, failed to significantly improve levels of prostate-specific antigen after 12 weeks of treatment and did not improve overall survival in men with metastatic castrate-resistant PCa (63). This evidence concerns the gene IGF1R and posterior cortical atrophy.